Serum Cytokeratin-18 as a Noninvasive Biomarker of Hepatocellular Injury in Patients with β-thalassemia
Journal of Applied Hematology · 2026-04 · 17 (2) · 136-142
DOI: 10.4103/joah.joah_22_26 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Applied Hematology, online erschienen am 12.06.2026. Verfasst von Hussein Yusuf Khanyab und 2 weiteren Autor:innen. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
BACKGROUND: Chronic transfusion therapy in β-thalassemia causes progressive iron overload and oxidative hepatocellular injury. Conventional markers, such as serum ferritin and aminotransferases, are limited by their lack of specificity, highlighting the need for reliable, noninvasive biomarkers of hepatic necrosis. OBJECTIVE: To evaluate serum cytokeratin-18 (CK-18) as a biomarker of hepatocellular injury in patients with β-thalassemia and to compare its levels between transfusion-dependent β-thalassemia (TDT) and non-transfusion-dependent β-thalassemia (NTDT) cohorts. MATERIALS AND METHODS: We conducted a cross-sectional study that enrolled 160 patients with confirmed beta-thalassemia (130 TDT and 30 NTDT) at the Hereditary Blood Disorder Center, Karbala Teaching Hospital for Maternity and Children (November 2024–December 2025). Serum CK-18, alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), and ferritin levels were measured. We used an independent samples t -test and Pearson correlation analysis. RESULTS: TDT patients exhibited significantly higher serum concentrations of CK-18 (353.9 ± 189.4 vs. 64.1 ± 20.7 pg/mL; P < 0.01), ferritin (2566.3 ± 1873.5 vs. 134.2 ± 115.5 ng/mL; P < 0.01), and all liver enzymes than NTDT patients. CK-18 concentration significantly correlated with those of ALT ( r = 0.388), AST ( r = 0.384), ALP ( r = 0.264), and ferritin ( r = 0.415; all P < 0.01). Patients with elevated liver enzyme levels had substantially higher CK-18 concentrations than those with normal enzyme levels ( P < 0.01). CONCLUSION: Serum CK-18 levels were significantly elevated in transfusion-dependent β-thalassemia and consistently correlated with established hepatic injury markers, confirming its utility as a sensitive, noninvasive indicator of ongoing hepatocellular death.
Zitieren
APA
Khanyab, H. Y., Mahmood, I. S., & Dagher, E. A. K. (2026). Serum Cytokeratin-18 as a Noninvasive Biomarker of Hepatocellular Injury in Patients with β-thalassemia. Journal of Applied Hematology, 17(2), 136-142. https://doi.org/10.4103/joah.joah_22_26
Vancouver
Khanyab HY, Mahmood IS, Dagher EAK. Serum Cytokeratin-18 as a Noninvasive Biomarker of Hepatocellular Injury in Patients with β-thalassemia. Journal of Applied Hematology. 2026;17(2):136-142. doi:10.4103/joah.joah_22_26
BibTeX
@article{Khanyab2026,
author = {Khanyab, Hussein Yusuf and Mahmood, Ihsan Shakir and Dagher, Enass Abdul Kareem},
title = {Serum Cytokeratin-18 as a Noninvasive Biomarker of Hepatocellular Injury in Patients with β-thalassemia},
journal = {Journal of Applied Hematology},
year = {2026},
volume = {17},
number = {2},
pages = {136--142},
doi = {10.4103/joah.joah_22_26}
}
EUVIMED